Yan P, Xu Z, Hui X, Chu X, Chen Y, Yang C
BMC Med Res Methodol. 2025; 25(1):58.
PMID: 40025462
PMC: 11872325.
DOI: 10.1186/s12874-025-02516-2.
Wu Y, Yin T, Jian G, Wan T, Zhou B
Front Pharmacol. 2024; 15:1373333.
PMID: 39376608
PMC: 11456474.
DOI: 10.3389/fphar.2024.1373333.
Zhu D, Feng J, Guo J, Duan J, Yang Y, Leng J
J Thorac Dis. 2024; 16(7):4447-4459.
PMID: 39144299
PMC: 11320233.
DOI: 10.21037/jtd-23-1876.
Cheng Y, Zhao Y, Xu M, Du H, Sun J, Yao Q
Front Immunol. 2024; 15:1386071.
PMID: 38881899
PMC: 11176469.
DOI: 10.3389/fimmu.2024.1386071.
Chen J, Xu L, Cheng J, Xu X
World J Clin Cases. 2024; 12(9):1704-1711.
PMID: 38576733
PMC: 10989423.
DOI: 10.12998/wjcc.v12.i9.1704.
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced -Mutated NSCLC.
Gulikers J, Veerman G, Jebbink M, Kruithof P, Steendam C, Boosman R
JTO Clin Res Rep. 2024; 5(4):100656.
PMID: 38550297
PMC: 10973185.
DOI: 10.1016/j.jtocrr.2024.100656.
Risk Factors of Venous Thromboembolism in Inpatients With Colorectal Cancer in China.
Chen F, Sun Y, Zhang C, Li L, Du Y, Zhou M
Clin Appl Thromb Hemost. 2023; 29:10760296231221133.
PMID: 38105233
PMC: 10729642.
DOI: 10.1177/10760296231221133.
Establishment and Validation of a Postoperative VTE Prediction Model in Patients with Colorectal Cancer Undergoing Radical Resection: CRSPOT Nomogram.
Wu Y, Wang L, Yin Q, Deng L, Ma J, Tian X
Clin Appl Thromb Hemost. 2023; 29:10760296231216966.
PMID: 37997283
PMC: 10668569.
DOI: 10.1177/10760296231216966.
Feasibility and safety of hybrid transvaginal natural orifice transluminal endoscopic surgery for colon cancer: Protocol for a multicenter, single-arm, phase II trial (vNOTESCA).
Fu T, Ren J, Yao H, Huang B, Sun L, Li X
Heliyon. 2023; 9(10):e20187.
PMID: 37780770
PMC: 10539939.
DOI: 10.1016/j.heliyon.2023.e20187.
Management of Thromboembolic Disease in Patients with Primary and Metastatic Brain Tumors.
Woods R, Lesser G
Curr Treat Options Oncol. 2023; 24(9):1293-1303.
PMID: 37407888
PMC: 10477143.
DOI: 10.1007/s11864-023-01116-w.
Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France.
Bertoletti L, Gusto G, Quignot N, Khachatryan A, Chaves J, Moniot A
Cancers (Basel). 2023; 15(11).
PMID: 37296971
PMC: 10251904.
DOI: 10.3390/cancers15113011.
Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study.
Plaisance L, Chapelle C, Laporte S, Planquette B, Bertoletti L, Falvo N
J Cancer Sci Clin Ther. 2023; 5(3):347-362.
PMID: 37169025
PMC: 10167753.
DOI: 10.26502/jcsct.5079122.
Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review.
Xiong W, Guo X, Du H, Xu M, Zhao Y
BMJ Open Respir Res. 2023; 10(1).
PMID: 37068846
PMC: 10111887.
DOI: 10.1136/bmjresp-2022-001493.
Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.
Shao Y, Ho C, Chang C, Chang C, Lee J, Lin H
Acta Cardiol Sin. 2023; 39(2):242-253.
PMID: 36911539
PMC: 9999188.
DOI: 10.6515/ACS.202303_39(2).20220719A.
Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism.
Song Y, Yang D, Hou D, She J, Song Y
Thromb J. 2023; 21(1):16.
PMID: 36732741
PMC: 9893535.
DOI: 10.1186/s12959-023-00453-y.
A Review of the Past, Present and Future of Cancer-associated Thrombosis Management.
Ramcharitar R, Man L, Khaja M, Barnett M, Sharma A
Heart Int. 2023; 16(2):117-123.
PMID: 36721704
PMC: 9870322.
DOI: 10.17925/HI.2022.16.2.117.
Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
Moufarrij S, Sassine D, Basaran D, Jewell E
Gynecol Oncol. 2023; 170:167-171.
PMID: 36701837
PMC: 10023346.
DOI: 10.1016/j.ygyno.2023.01.012.
Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study.
Boileve A, Albiges L, Ducreux M, Baudin E, Leary A, Besse B
Support Care Cancer. 2022; 31(1):41.
PMID: 36525139
DOI: 10.1007/s00520-022-07533-1.
Prevalence and treatment of venous thromboembolism in patients with solid tumors.
Zhao H, Liang F, Ling Y, Li T, Fang B, Deng T
Exp Ther Med. 2022; 24(6):743.
PMID: 36478882
PMC: 9716337.
DOI: 10.3892/etm.2022.11679.
Risk of Recurrent Venous Thromboembolism in Selected Subgroups of Men: A Danish Nationwide Cohort Study.
Albertsen I, Konstantinides S, Piazza G, Goldhaber S, Larsen T, Sogaard M
TH Open. 2022; 6(4):e378-e386.
PMID: 36452198
PMC: 9674434.
DOI: 10.1055/a-1949-9404.
